Art

J-GLOBAL ID：202202220694417206   Reference number：22A1181159

Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk

中間脳卒中リスクを有する心房細動患者における直接経口抗凝固薬対ワルファリンの費用対効果【JST・京大機械翻訳】

Author (8)： Choi Ju Hee (Department of Public Health, Graduate School, Yonsei University, Seoul, South Korea) ,  Kim Woojin (Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea) ,  Kim Yun Tae (Department of Public Health, Graduate School, Yonsei University, Seoul, South Korea) ,  Cho Jaelim (Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea) ,  Shin Seung Yong (Division of Cardiology, Chung-Ang University Hospital, Seoul, South Korea) ,  Kim Changsoo (Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, South Korea) ,  Kim Changsoo (Institute of Human Complexity and Systems Science, Yonsei University, Incheon, South Korea) ,  Kim Jin-Bae (Division of Cardiology, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, South Korea)
Material： Frontiers in Cardiovascular Medicine (Web)
Volume： 9  Page： 849474  Publication year： 2022 
JST Material Number： U7061A  ISSN： 2297-055X  Document type： Article
Article type： 原著論文  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： Background: Several studies ha...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=22A1181159&from=J-GLOBAL&jstjournalNo=U7061A") }}

Thesaurus term： *risk ,  *anticoagulant ,  *auricular fibrillation ,  *patient ,  complication ,  gastrointestinal hemorrhage ,  cerebral hemorrhage ,  lactone ,  polynuclear aromatic compound ,  hydroxy ketone
Semi thesaurus term： *費用対効果 ,  *経口抗凝固薬 ,  *脳卒中リスク ,  *NOAC , 【Automatic Indexing@JST】

Author keywords (5)： atrial fibrillation ,  cost-effectiveness ,  anticoagulants ,  warfarin ,  intermediate stroke risk

JST classification (2)： Drug therapy(=pharmacotherapy)for cardiovascular system diseases  (GJ05020M) ,  Clinical application of drugs acting on blood and body fluid  (GW14020X)

Substance index (5)： Rivaroxaban ,  Apixaban ,  Edoxaban ,  Dabigatran ,  Warfarin

Reference (37)：

• Fang MC, Chen J, Rich MW. Atrial fibrillation in the elderly. Am J Med. (2007) 120:481-7. doi: 10.1016/j.amjmed.2007.01.026
• Joung B, Lee JM, Lee KH, Kim TH, Choi EK, Lim WH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J. (2018) 48:1033-80. doi: 10.4070/kcj.2018.0339
• Sheikh A, Patel NJ, Nalluri N, Agnihotri K, Spagnola J, Patel A, et al. Trends in hospitalization for atrial fibrillation: epidemiology, cost, and implications for the future. Prog Cardiovasc Dis. (2015) 58:105-16. doi: 10.1016/j.pcad.2015.07.002
• Kim MH, Johnston SS, Chu B-C, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. (2011) 4:313-20. doi: 10.1161/CIRCOUTCOMES.110.958165
• Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda J-G, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. (2011) 13:1375-85. doi: 10.1093/europace/eur194

Terms in the title (6)： 脳卒中リスク ,  心房細動 ,  患者 ,  直接経口抗凝固薬 ,  ワルファリン ,  費用対効果